The weekly litigation news digest is live. Subscribe now

IP Verse

Proteolytically Cleavable Fusion Protein Comprising A Blood Coagulation Factor - EP2256135

The patent EP2256135 was granted to CSL Behring on Mar 13, 2019. The application was filed on Jun 14, 2007 under application number EP10168453A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2256135

CSL BEHRING
Application Number
EP10168453A
Filing Date
Jun 14, 2007
Status
Granted And Under Opposition
Feb 8, 2019
Publication Date
Mar 13, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
BIOVERATIV THERAPEUTICSDec 13, 2019ZWICKERWITHDRAWN

Patent Citations (18) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS4784950
DESCRIPTIONWO0179271
DESCRIPTIONWO0204598
DESCRIPTIONWO03059935
DESCRIPTIONWO03068934
DESCRIPTIONWO2004081053
DESCRIPTIONWO2004101740
DESCRIPTIONWO2005001025
DESCRIPTIONWO2005024044
DESCRIPTIONWO9109125
EXAMINATIONEP1816201
OPPOSITIONEP1444986
OPPOSITIONWO2004101740
SEARCHEP1444986
SEARCHWO2004021861
SEARCHWO2004101739
SEARCHWO2004101740
SEARCHWO9601653

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents